Are IL4 rs2243250 and ORMDL3 rs7216389 variants linked to allergic and type-2 immune conditions?

Genetic variations in the IL4 and ORMDL3 genes represent critical risk factors for susceptibility to type-2 immune-mediated conditions, including asthma, allergic rhinitis, and atopic inflammation.

Clinical evidence and phenotypic risk

• IL4 rs2243250 (-589C/T): The risk T allele and TT genotype of this promoter variant are consistently linked to heightened susceptibility to atopic asthma, allergic rhinitis, and general atopic allergy across dominant, recessive, and allelic genetic models.
• ORMDL3 rs7216389: The risk T allele correlates strongly with childhood-onset asthma (OR ≈ 1.41–1.45) and severe asthma phenotypes (OR ≈ 2.02), with minimal association in adult-onset cohorts. It is also linked to elevated type-2 markers, including high IgE levels (OR ≈ 1.55), high fractional exhaled nitric oxide (FeNO), and increased eosinophils.

Biological and mechanistic pathways

• IL-4 overexpression and Th2 skewing: The rs2243250 C-to-T promoter transition enhances transcription factor binding and promoter activity, elevating IL-4 cytokine levels. This skews immune responses toward helper T cell type 2 (Th2) differentiation and drives B-cell immunoglobulin class-switching to IgE, increasing total serum IgE.
• Sphingolipid metabolic pathway disruption: The rs7216389 variant functions as a strong expression quantitative trait locus (eQTL) where the risk T allele increases ORMDL3 mRNA levels. Elevated ORMDL3 protein negatively regulates serine palmitoyltransferase (SPT), the rate-limiting enzyme in de novo sphingolipid synthesis, leading to diminished levels of whole-blood dihydroceramides and ceramides.

Bottom line

• The IL4 rs2243250 and ORMDL3 rs7216389 variants are robustly associated with susceptibility to allergic and type-2 immune conditions. This susceptibility is driven by distinct functional mechanisms: IL4 variants enhance Th2-mediated IgE responses, while ORMDL3 variants disrupt airway immune homeostasis by downregulating de novo sphingolipid biosynthesis.